Literature DB >> 263883

Treatment of osteomyelitis and septic arthritis with cefazolin.

R J Fass.   

Abstract

Sixteen cases of severe osteomyelitis and septic arthritis caused by staphylococci, streptococci, gonococci, and a variety of gram-negative bacilli were treated with 4 to 8 g of parenteral cefazolin per day; nine received subsequent therapy with oral cephalexin or ampicillin. Of 16 infections, 15 were apparently cured. Cefazolin concentrations in those patients were: serum (peak), 25 to 216 micrograms/ml; synovial fluid, 24 to 46 micrograms/ml; and bone, 3.2 to 10.6 micrograms/g. Bacterial pathogens had minimal inhibitory concentrations of cefazolin of 2 micrograms or less per ml and seemed to be eradicated from foci of infection during therapy. One infection in a diabetic patient did not respond; despite high concentrations of cefazolin in serum, no detectable antibiotic was present in her infected metatarsal, and the infecting Escherichia coli (minimal inhibitory concentration, 16 micrograms/ml) was not eradicated during therapy. Concentrations of cefazolin in bone in 10 uninfected patients who received 1-g intramuscular doses prophylactically before surgery were also measured. Concentrations in bones from those who had normal renal function ranged from less than 0.6 to 2.8 micrograms/g.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 263883      PMCID: PMC352253          DOI: 10.1128/AAC.13.3.405

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Bone concentrations of antimicrobial agents after parenteral administration.

Authors:  J D Smilack; W H Flittie; T W Williams
Journal:  Antimicrob Agents Chemother       Date:  1976-01       Impact factor: 5.191

2.  Aerobic and anaerobic bacteria in diabetic foot ulcers.

Authors:  T J Louie; J G Bartlett; F P Tally; S L Gorbach
Journal:  Ann Intern Med       Date:  1976-10       Impact factor: 25.391

3.  Comparative evaluation of cefazolin and cephalothin in children.

Authors:  L K Pickering; D M O'Connor; D Anderson; A C Bairan; R D Feigin; J D Cherry
Journal:  J Pediatr       Date:  1974-12       Impact factor: 4.406

4.  Pharmacokinetics of cefazolin compared with four other cephalosporins.

Authors:  W M Kirby; C Regamey
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

5.  In vitro activity of cefazolin against recent clinical bacterial isolates.

Authors:  L D Sabath; C Wilcox; C Garner; M Finland
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

6.  Interaction of clindamycin and gentamicin in vitro.

Authors:  R J Fass; C A Rotilie; R B Prior
Journal:  Antimicrob Agents Chemother       Date:  1974-11       Impact factor: 5.191

7.  Effectiveness of two new cephalosporins, cephazolin and cephapirin, administered intermittently in acute and chronic osteomyelitis in children.

Authors:  J L Arango; H Trujillo; D Worren; A Uribe; N H Agudelo; E L de Vidal
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

8.  Treatment of the gonococcal arthritis-dermatitis syndrome.

Authors:  H H Handsfield; P J Wiesner; K K Holmes
Journal:  Ann Intern Med       Date:  1976-06       Impact factor: 25.391

9.  Microbioassay of antimicrobial agents.

Authors:  H J Simon; E J Yin
Journal:  Appl Microbiol       Date:  1970-04

10.  Evaluation of cefazolin, a new cephalosporin antibiotic.

Authors:  L B Reller; W W Karney; H N Beaty; K K Holmes; M Turck
Journal:  Antimicrob Agents Chemother       Date:  1973-04       Impact factor: 5.191

View more
  6 in total

Review 1.  Staphylococcal adaptation to diverse physiologic niches: an overview of transcriptomic and phenotypic changes in different biological environments.

Authors:  Sana S Dastgheyb; Michael Otto
Journal:  Future Microbiol       Date:  2015-11-19       Impact factor: 3.165

2.  Ofloxacin versus parenteral therapy for chronic osteomyelitis.

Authors:  L O Gentry; G Rodriguez-Gomez
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 3.  Systemic antibiotic therapy for chronic osteomyelitis in adults.

Authors:  Brad Spellberg; Benjamin A Lipsky
Journal:  Clin Infect Dis       Date:  2011-12-12       Impact factor: 9.079

4.  Continuous cefazolin infusion to treat bone and joint infections: clinical efficacy, feasibility, safety, and serum and bone concentrations.

Authors:  Valérie Zeller; Frédérick Durand; Marie-Dominique Kitzis; Luc Lhotellier; Jean-Marc Ziza; Patrick Mamoudy; Nicole Desplaces
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

5.  Bacterial and Lyme Arthritis.

Authors:  John J Ross; Linden T Hu
Journal:  Curr Infect Dis Rep       Date:  2004-10       Impact factor: 3.725

Review 6.  Acute infectious osteomyelitis in children: new treatment strategies for an old enemy.

Authors:  Sabrina Congedi; Chiara Minotti; Carlo Giaquinto; Liviana Da Dalt; Daniele Donà
Journal:  World J Pediatr       Date:  2020-05-11       Impact factor: 2.764

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.